Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of PTM-101 as Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Next Previous
X
Search
Trial Profile

A Phase I Study of PTM-101 as Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors PanTher Therapeutics

    • Most Recent Events

    • 10 Apr 2024 Results presented at the 115th Annual Meeting of the American Association for Cancer Research
    • 08 Apr 2024 According to a PanTher Therapeutics Media Release, Charles Pilgrim is the principal investigator of the PTM-101 phase 1 clinical trial.
    • 08 Apr 2024 According to a PanTher Therapeutics Media Release, positive data from this study presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10th in San Diego.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top